Biofeedback training for Stroke

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Toronto Western Hospital, Toronto, Canada
Stroke+10 More
Biofeedback training - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Patients with brain injury secondary to stroke, surgery, or trauma frequently suffer from homonymous hemianopia, defined as vision loss in one hemifield secondary to retro- chiasmal lesion. Classic and effective saccadic compensatory training therapies are current aim to reorganize the control of visual information processing and eye movements or, in other words, to induce or improve oculomotor adaptation to visual field loss. Patients learn to intentionally shift their eyes and, thus, their visual field border, into the area corresponding to their blind visual field. This shift brings the visual information from the blind hemifield into the seeing hemifield for further processing. Patients learn, therefore, to efficiently use their eyes "to keep the 'blind side' in sight". Biofeedback training (BT) is the latest and newest technique for oculomotor control training in cases with low vision when using available modules in the new microperimetry instruments. Studies in the literature highlighted positive benefits from using BT in a variety of central vision loss, nystagmus cases, and others.The purpose of this study is to assess systematically the impact of BT in a series of cases with hemianopia and formulate guidelines for further use of this intervention in vision rehabilitation of hemianopia cases in general.

Eligible Conditions

  • Stroke
  • Brain
  • Homonymous Hemianopia
  • Injuries, Brain
  • Neoplasms, Brain

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

6 Primary · 2 Secondary · Reporting Duration: 1 week post biofeedback

1 week post biofeedback
Contrast Sensitivity
Fixation stability
Near vision
Quality of Life Questionnaire scores
Reading speed
Retinal sensitivity
Stereopsis
Visual Acuity

Trial Safety

Trial Design

2 Treatment Groups

Group B
1 of 2
Group A
1 of 2
Active Control
Experimental Treatment

32 Total Participants · 2 Treatment Groups

Primary Treatment: Biofeedback training · No Placebo Group · N/A

Group A
Device
Experimental Group · 1 Intervention: Biofeedback training · Intervention Types: Device
Group BNoIntervention Group · 1 Intervention: Group B · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biofeedback training
2013
N/A
~370

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week post biofeedback
Closest Location: Toronto Western Hospital · Toronto, Canada
Photo of Toronto 1Photo of Toronto 2Photo of Toronto 3
2011First Recorded Clinical Trial
12 TrialsResearching Stroke
200 CompletedClinical Trials

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,351 Previous Clinical Trials
471,601 Total Patients Enrolled
21 Trials studying Stroke
5,715 Patients Enrolled for Stroke
University of TorontoOTHER
622 Previous Clinical Trials
719,348 Total Patients Enrolled
21 Trials studying Stroke
3,923 Patients Enrolled for Stroke

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Hemianopia cases previously diagnosed accordingly by microperimetry and other tests as needed.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.